Page 109 - Read Online

Page 8 of 12 Zhang et al. Hepatoma Res 2020;6:40 I http://dx.doi.org/10.20517/2394-5079.2020.20

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCE
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Tian Y, Yang B, Qiu W, Hao Y, Zhang Z, et al. ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic
reprogramming of oxLDL lipophagy. Nat Commun 2019;10:3391.
3. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B:
assessment and modification with current antiviral therapy. J Hepatol 2015;62:956-67.
4. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with
increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology 2019;157:1253-63.e2.
5. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and
management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.
6. Desert R, Rohart F, Canal F, Sicard M, Desille M, et al. Human hepatocellular carcinomas with a periportal phenotype have the lowest
potential for early recurrence after curative resection. Hepatology 2017;66:1502-18.
7. Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev
Gastroenterol Hepatol 2019;16:617-30.
8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in
cancer. N Engl J Med 2012;366:2443-54.
9. Mason R, Au L, Ingles Garces A, Larkin J. Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opin
Pharmacother 2019;20:1135-52.
10. Administration UFaD. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. 2017. Available
from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606540.htm [Last accessed on 16 Jun 2020]
11. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B
lymphocytes. Int Immunol 1996;8:765-72.
12. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat
Immunol 2001;2:261-8.
13. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family
member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.
14. Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther
2018;18:1169-75.
15. Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, et al. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.
Clin Cancer Res 2017;23:7333-9.
16. Mocan T, Sparchez Z, Craciun R, Bora CN, Leucuta DC. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1)
axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol 2019;21:702-12.
17. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative
recurrence in hepatocellular carcinoma patients. Int J Cancer 2011;128:887-96.
18. Long J, Qu T, Pan XF, Tang X, Wan HH, et al. Expression of programmed death ligand-1 and programmed death 1 in hepatocellular
carcinoma and its clinical significance. J Cancer Res Ther 2018;14:S1188-92.
19. Ma LJ, Feng FL, Dong LQ, Zhang Z, Duan M, et al. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in
patients with hepatocellular carcinoma. Theranostics 2018;8:5690-702.
20. Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with
hepatocellular carcinoma. Cancer Res Treat 2017;49:246-54.
21. Liu CQ, Xu J, Zhou ZG, Jin LL, Yu XJ, et al. Expression patterns of programmed death ligand 1 correlate with different
microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer 2018;119:80-8.
22. Chang H, Jung W, Kim A, Kim HK, Kim WB, et al. Expression and prognostic significance of programmed death protein 1 and
programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma. Apmis 2017;125:690-8.
23. Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival
in HCC. Cancer Immunol Res 2016;4:419-30.
24. Huang CY, Wang Y, Luo GY, Han F, Li YQ, et al. Relationship between PD-L1 expression and CD8+ T-cell immune responses in
hepatocellular carcinoma. J Immunother 2017;40:323-33.
25. Umemoto Y, Okano S, Matsumoto Y, Nakagawara H, Matono R, et al. Prognostic impact of programmed cell death 1 ligand 1 expression
in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol 2015;50:65-75.
26. Chang B, Huang T, Wei H, Shen L, Zhu D, et al. The correlation and prognostic value of serum levels of soluble programmed death